Atlas Trials

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Clinical trial NCT03250338 · COMPLETED

Trial details

NCT number
NCT03250338
Sponsor
Arog Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Start date
2018-08-16
Primary completion
2026-04-03
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.